In vitro evolution of chemically-modified nucleic acid aptamers: Pros and cons, and comprehensive selection strategies by Lipi, F. et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=krnb20
Download by: [Murdoch University Library] Date: 31 October 2017, At: 01:15
RNA Biology
ISSN: 1547-6286 (Print) 1555-8584 (Online) Journal homepage: http://www.tandfonline.com/loi/krnb20
In vitro evolution of chemically-modified nucleic
acid aptamers: Pros and cons, and comprehensive
selection strategies
Farhana Lipi, Suxiang Chen, Madhuri Chakravarthy, Shilpa Rakesh & Rakesh
N. Veedu
To cite this article: Farhana Lipi, Suxiang Chen, Madhuri Chakravarthy, Shilpa Rakesh &
Rakesh N. Veedu (2016) In vitro evolution of chemically-modified nucleic acid aptamers: Pros
and cons, and comprehensive selection strategies, RNA Biology, 13:12, 1232-1245, DOI:
10.1080/15476286.2016.1236173
To link to this article:  http://dx.doi.org/10.1080/15476286.2016.1236173
© 2016 The Author(s). Published with
license by Taylor & Francis Group, LLC©
Farhana Lipi, Suxiang Chen, Madhuri
Chakravarthy, Shilpa Rakesh, and Rakesh N.
Veedu
Accepted author version posted online: 07
Oct 2016.
Published online: 07 Oct 2016.
Submit your article to this journal Article views: 920
View related articles View Crossmark data
Citing articles: 15 View citing articles 
REVIEW
In vitro evolution of chemically-modified nucleic acid aptamers: Pros and cons, and
comprehensive selection strategies
Farhana Lipi a, Suxiang Chena,b, Madhuri Chakravarthya,b, Shilpa Rakesha, and Rakesh N. Veedua,b
aWestern Australian Neuroscience Research Institute, Perth, Australia; bCentre for Comparative Genomics, Murdoch University, Perth, Australia
ARTICLE HISTORY
Received 29 July 2016
Revised 6 September 2016
Accepted 7 September 2016
ABSTRACT
Nucleic acid aptamers are single-stranded DNA or RNA oligonucleotide sequences that bind to a specific
target molecule with high affinity and specificity through their ability to adopt 3-dimensional structure in
solution. Aptamers have huge potential as targeted therapeutics, diagnostics, delivery agents and as
biosensors. However, aptamers composed of natural nucleotide monomers are quickly degraded in vivo
and show poor pharmacodynamic properties. To overcome this, chemically-modified nucleic acid
aptamers are developed by incorporating modified nucleotides after or during the selection process by
Systematic Evolution of Ligands by EXponential enrichment (SELEX). This review will discuss the
development of chemically-modified aptamers and provide the pros and cons, and new insights on in
vitro aptamer selection strategies by using chemically-modified nucleic acid libraries.
Abbreviations: SELEX, Systematic Evolution of Ligands by EXponential enrichment; US FDA, United States Food and
Drug Administration; AMD, Age-related macular degeneration; VEGF, Vascular endothelial growth factor protein, 20-
NH2, 20-Amino; 20-OH, 20-Hydroxyl; Kd, Equilibrium dissociation constant; 20-OMe, 20-O-Methyl; Bfgf, Basic fibroblast
growth factor; 20-F, 20-Fluoro; PSMA, Prostate specific membrane antigen; IFN-g , Interferon-gamma; KGF, Keratino-
cyte growth factor; 40-S, 40-Thio; 20-FANA, 20-Fluroarabino nucleic acid; HNA, 1,5-Anhydro hexitol nucleic acid; TAR,










Nucleic acid aptamer technology has attracted considerable
attention in recent years in light of their widespread applica-
tions in therapeutic development, targeted drug delivery, bio-
sensing and accurate molecular imaging. Aptamers are short
single-stranded DNA or RNA oligonucleotides with unique 3-
dimensional shape that can bind to their specific target with
very high affinity and specificity.1-5 Aptamers are generally
developed from a large pool of oligonucleotide libraries con-
taining approximately 1014 members by a reiterative process
referred to as SELEX which involves selection, separation and
enrichment steps (Fig. 1).6,7 Till now, antibodies have been
widely used for target specific molecular recognition.8 However,
compared to antibody-based technologies, aptamers may pos-
sess a number of advantages including easy laboratory produc-
tion in vitro effectively eliminating the use of live animals, no
batch to batch variation, low or no immunogenicity, freedom
to introduce multiple chemistries during synthesis without los-
ing the affinity and specificity, small size that allows faster tis-
sue penetration, ability to reverse target binding interactions
using its complementary antidote sequence, significantly longer
shelf-life and low cost. In 2004, an aptamer drug Macugen
(Pegaptanib Sodium) was approved by United States Food and
Drug Administration (US FDA) for the treatment of neovascu-
lar age-related macular degeneration (AMD) by targeting
vascular endothelial growth factor protein 165 (VEGF165).
9,10
Currently, a number of aptamer-based therapeutic candidates
are in preclinical development and in different stages of clinical
trials.11
Typically, aptamers are developed with naturally occur-
ring nucleotides. However, aptamers composed of natural
nucleotide monomers are not suitable for theranostic appli-
cations as they possess very poor resistance to enzymatic
degradation and show decreased binding affinity, rendering
poor pharmacokinetic properties. To circumvent these
shortcomings, aptamers containing chemically-modified
nucleotide analogs with high stability against nucleases are
normally used. Early examples of modified aptamers were
primarily produced by post-SELEX-based approach. In this
process, the aptamers were first isolated using natural RNA
or DNA random sequences by SELEX method and then
modified as per demand on affinity, stability and functional-
ity. For this purpose, appropriate chemically-modified
nucleotides are systematically incorporated into an existing
DNA/RNA aptamer during solid-phase oligonucleotide syn-
thesis. Generally, a web-based secondary structure predic-
tion algorithm (e.g. mfold,12 RNAfold13) is used as a tool to
assist with the positioning of chemically-modified nucleoti-
des and to truncate the overall size of the selected aptamers
during chemical synthesis. Such chemically-fabricated
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aptamer variants are then tested for binding affinity, and
the best candidates are used for further analysis and down-
stream applications in vitro and in vivo. Evolution of chem-
ically-modified aptamers would be a far more powerful
approach to develop modified aptamers as this could gener-
ate aptamers with unique structures and with even shorter
libraries.
Evolution of chemically-modified aptamers
A large repertoire of chemically-modified nucleotide analogs
with remarkable biophysical properties have been developed in
recent years and a few papers have reviewed the use of these
chemically-modified nucleotides in the generation of aptamers
and nucleic acids with enzymatic activity including DNAzymes
and ribozymes.14-18 But, their applicability in de novo evolution
of aptamers via SELEX methodologies are rather impeded by
poor or lack of enzymatic recognition capabilities. Conven-
tional selection methodologies involve multiple enzymatic steps
that are required to amplify and regenerate chemically-modi-
fied nucleotide-containing libraries. Some sugar-modified
nucleotides are reported to tolerate few commercially available
DNA or RNA polymerases,19 making them promising candi-
dates for aptamer selection. However, it is worth mentioning
that the level of enzymatic recognition capabilities of the
reported modified nucleotides varies depending on the specific
chemical modification. Still, the substrate properties of a num-
ber of other promising analogs have not been reported which
might be due to the lack of enzymatic recognition. One option
is to evolve an enzyme specific to the modified nucleotide, and
there are reports of successful aptamer selection using engi-
neered enzymes for chemically-modified nucleotides.20,21 An
overview of possible strategies that can be applied for selecting
chemically-modified aptamers are outlined below (Fig. 2).
Generation of chemically-modified libraries and
selection strategies
Starting oligonucleotide libraries containing the desired chemi-
cally-modified nucleotide or a combination of different modifi-
cations can be chemically synthesized using an oligonucleotide
synthesizer via standard phosphoramidite chemistry. Another
approach could be to synthesize normal DNA library which
subsequently can be converted to a chemically-modified library
by following enzymatic protocols involving PCR and/or in vitro
transcription reactions with modified nucleotide triphosphates
using the specific polymerase which could also be used in sub-
sequent amplification/regeneration steps of multiple selection
rounds. Synthetic chemically-modified libraries can be con-
structed by incorporating the modified nucleotides in the ran-
domized region or in the primer-binding region.
Library with modified random region
Modified nucleotides can be incorporated as mixmers together
with natural nucleotide monomers or as fully modified in the
random region to furnish a chemically-modified oligonucleo-
tide library for aptamer selection. However, the libraries con-
taining fully modified random region with all four modified
nucleotide bases may be limited to use in one-step aptamer
selection-based methodologies. This is mainly because the
selected aptamer candidates are regenerated using triphosphate
derivatives of the corresponding modified nucleotides, but dur-
ing an enzymatic synthesis process, the primer-binding region
will also be modified with the same modified nucleotides con-
trary to the starting library design. In SELEX to allow maxi-
mum base variations of the chemically-modified nucleotides
(good substrates of specific enzymes) in the random region, the
nucleotide bases can be mixed with one, two or three modified





































nucleotide bases of the same or different nucleotide analogs in
combination with the natural counterparts. But, depending on
the number of modified nucleotide bases in the randomized
region, the primer-binding region needs to be adjusted with the
base composition of unmodified nucleotides. In this approach,
where nucleotide mixmers are randomized, it is difficult to
locate the positioning of modified nucleotide analogs, and if the
library is constructed with successive stretch of modified
nucleotides it may be hard for the polymerases to regenerate
these particular sequences for subsequent selection rounds.
Another design approach could be to fix the positioning
of modified nucleotides in the random region, which will
assist to keep track of the positioning of modified nucleotides
after sequencing. But, this could limit the pool diversity to
some extent, however, it is worthwhile to perform selection
since some chemical modifications could generate unique
shapes and enhance target binding affinity. It is best to limit
up to two fixed modifications that could be incorporated
individually at different positions or as a mixture at the
same positions allowing two nucleotide variations. Again,
the primer-binding region needs to be constructed only with
the unmodified natural nucleotide bases (avoiding similar
base counterparts of the chemically-modified nucleotides) to
regenerate the selected aptamer candidates for use in the
subsequent selection rounds. During the sequence alignment
after sequencing, only those candidates that maintain the
initial library design need to be considered for further
analysis and chemical synthesis.
Library with modified primer-binding region
For some modified nucleotide analogs that offer potential bio-
physical properties, enzymatic recognition may be difficult lim-
iting their application in aptamer selection using conventional
SELEX method. But, such modifications can still be used in
aptamer selection using a library with one of the primer-bind-
ing regions containing the desired chemically-modified nucleo-
tides, and the other region with all four natural nucleotide
monomers. This will essentially eliminate the need of an enzy-
matic recognition of modified nucleotides as a synthetic primer
sequence with the chemical modifications can be used during
the enrichment steps. But, the protocol may be limited to
DNA-based oligonucleotides. This approach may not fit very
well in line to the concept of aptamer selection where it is spec-
ulated that the randomized region would promote the forma-
tion of target-binding motifs due to high sequence variability.
But, one cannot ignore the fact that a part of the primer-
binding region also plays a role in the folding pattern of the
binding aptamers in majority of the cases. On this ground,
aptamer selection using a library with chemically-modified
primer-binding regions can be well justified, and can be used as
an alternate approach. This method has been successfully
applied for generating LNA-modified aptamers.22,23
1-aptamer library
Aptamer selections can also be performed using a library con-
taining infinite range (1) of modified nucleotides with non-
natural structural chemistries of the nucleobase, sugar and
phosphate backbone. Libraries containing infinite nucleotides
could come with diverse range of chemistries bearing positive
charges, hydrophobic groups, phosphorothioates, amino acids
etc. that could improve and enhance the target binding interac-
tions and nuclease resistance. Such libraries are mainly suitable
for one-step selection protocols.24-27 1-nucleotides can be best
positioned in the randomized regions. During synthesis,
1-nucleotides of all four bases can also be mixed with their
natural counterparts.
Aptamer selection using sugar-modified nucleotides
Modifications of sugars will result in libraries with a greater
functional diversity and can form stable aptamers with unique
shapes. Sugar modifications could allow screening of ligands
that bind with greater affinity to their targets than their unmod-
ified counterparts. These unnatural modifications are less likely
to be recognized by nucleases, making them more stable in
serum. Most frequently, chemical modifications are introduced
at the 20-position of the nucleotide for increased nuclease resis-
tance, and binding affinity. The SELEX evolution of various
sugar- modified nucleotide (Fig. 3) containing aptamers against
different targets, their binding affinities and stabilities are
described below. Table 1 shows an overview of sugar-modified
aptamer development in recent years.
Figure 2. The construction of oligonucleotide libraries for developing chemically modified libraries.




































20-Amino (20-NH2) modified aptamers
Aptamers have been selected from libraries where the 20-
hydroxyl (20-OH) group of the pyrimidine is replaced by a NH2
group. A modified aptamer was screened from a 20-NH2 -modi-
fied RNA library involving 20-NH2-UTP and 20-NH2-CTP
replacing unmodified UTP and CTP during enrichment steps,
specific to the human neutrophil elastase using nitrocellulose
filter binding assay.28 The selected aptamers showed high affin-
ity to the target with the equilibrium dissociation constant (Kd)
in the range of 7–30 nM which is much lower than that of the
unmodified RNA aptamer (Kd > 1 mM).
28 These aptamers
were found to be very selective to human neutrophil elastase.28
These modified RNA aptamers also improved nuclease resis-
tance, with an extended half-life (20 h and 9 h in serum and
urine respectively) than the unmodified aptamer (degraded in
less than 8 and 5 mins in serum and urine respectively).28
Another 20-NH2-pyrimidine-modified RNA aptamer was
developed against VPF/VEGF by SELEX process.29 The affinity
was measured through nitrocellulose filter binding assay and
one aptamer NX-178 had a Kd of 2.4 nM, with an increased
half-life in urine (17 h).29 Interestingly the introduction of a 20-
O-Methyl (20-OMe) nucleotide post-SELEX further increased
the binding affinity to Kd D 0.14 nM and half-life in urine to
31 h.29 This study suggests that the affinity and nuclease resis-
tance of the RNA modified aptamers developed by SELEX
methodology can be further improved by post-SELEX modifi-
cation. In another study, Beaudry et al. developed a 20-NH2
pyrimidine-modified ribozyme which was identified by affinity
column-based SELEX.30 The selected aptamer had a half-life of
16 h in human serum, whereas the unmodified counterpart
degraded in serum in just 5 mins.30 Jellinek et al. developed a
different 20-NH2 pyrimidine-modified RNA aptamer, selected
through nitrocellulose membrane filter binding assay specific
to basic fibroblast growth factor (bFGF).31 The identified
aptamer m21A bound to bFGF with high binding affinity
(Kd D 0.35 nM).31 The stability of this aptamer in serum is 100
fold higher than the natural RNA aptamer.31 In another study,
Bugaut et al. used an interesting methodology whereby SELEX
and dynamic combinatorial chemistry were combined to select
conjugated RNA aptamers against MiniTAR by magnetic bead
immobilisation using a 20-NH2- modified RNA library. The
resulting conjugated aptamers developed bound to MiniTAR
with high affinity (Kd D 26–47 nM).32
20-fluoro (20-F) modified aptamers
Ruckman et al. developed an RNA aptamer specific to
VEGF165 isoform by nitrocellulose filter binding assay using 20-F
modified RNA libraries.33 Most of the selected 20-F RNA
aptamers had affinities for VEGF165 in the pM range (aptamer
with the lowest affinities had a Kd value of 2 pM).
33 This candi-
date aptamer after further chemical modifications has been
approved by the US FDA for the treatment of AMD. Lupold
et al. developed another 20-F modified RNA aptamer A10, target-
ing prostate specific membrane antigen (PSMA), cell surface
receptors expressed on prostate cancer cells by SELEX using
magnetic bead separation-based method.34 The aptamer A10
bound to PSMA with a Kd of 11.9 nM in LNCaP cells.
34 This was
later used to link siRNA to form aptamer-siRNA chimeras that
allowed targeted delivery of siRNA to cells expressing PSMA
wherein the siRNA reduced the expression of two survival genes,
Polo-like kinase 1 and B-cell lymphoma 2.34,35 In another study,
Biesecker et al. developed another aptamer against human com-
plement C5 component using 20-F pyrimidine-modified RNA
libraries by nitrocellulose membrane filter binding assay.36 The
aptamers generated had Kd of between 20–40 nM and this was
further improved by a second biased SELEX experiment where
the generated aptamers had a Kd of 2–5 nM.
36 The aptamers gen-
erated were able to bind to human complement C5 component
with high affinity and were able to inhibit its activity in human





































serum with high stability.36 Rusconi et al. developed 20-F modi-
fied aptamers for Factor II, Factor VII, Factor IX and Factor X
through nitrocellulose membrane filter binding assay.37,38 By this
approach a RNA aptamer was identified against Factor IXa with
the highest affinity (Kd of 0.64 nM), and was a potent anticoagu-
lant.38 Another aptamer generated against Factor IX had a Kd of
364 pM.37 Lamberti et al. developed an aptamer against Cancer
Antigen 125 by magnetic bead immobilisation using a 20-F
modified RNA library.39 Of the two RNA aptamers isolated,
CA125.1 had a Kd of 4.15 nM and can be developed further for
use as a diagnostic tool.39
Comparison of 20-F and 20-NH2 modifications
Various studies indicate that both 20-F and 20-NH2 modifica-
tions increase the nuclease resistance and binding affinity of
Table 1. Aptamers selected from sugar-modified DNA/RNA libraries and the binding affinity of aptamers to their targets.
Modified





T7 RNA polymerase 7–25 nM 28
VPF/VEGF Nitrocellulose membrane filter
binding
Y639F T7 RNA Polymerase 2.4 nM 29
mRNAs Affinity column T7 RNA polymerase No Kd (Kcat D 0.04 min¡1) 30
bFGF Nitrocellulose membrane filter
binding
Y639F T7 RNA Polymerase Apparent Kd D 0.35 nM 31
KGF Nitrocellulose membrane filter
binding
Y639F T7 RNA Polymerase 0.4 nM 41
IFN-g Nitrocellulose membrane filter
binding
Y639F T7 RNA Polymerase 1.8 nM 40
MiniTAR Magnetic bead immobilisation DNA polymerase 26–47 nM 32
20-F VEGF165 Nitrocellulose membrane filter
binding
T7 RNA Polymerase 2 pM 33
PSMA Magnetic bead immobilisation Y639F T7 RNA Polymerase No Kd (IC50 D 27 nM)






T7 RNA polymerase 2–5 nM 36
KGF Nitrocellulose membrane filter
binding





AMV Reverse Transcriptase Kd D 0.64 nM (9.3)
Kd D 364 pM (Clone 9D-6)
37,38
IFN-g Nitrocellulose membrane filter
binding
Y639F T7 RNA Polymerase 106 nM 40
IFN-g Nitrocellulose membrane filter
binding
Y639F T7 RNA Polymerase 6.8 nM 40
Cancer Antigen 125 Magnetic bead immobilisation Y639F T7 RNA Polymerase CA125.1 Kd D 4.13 nM 39
20-OMe VEGF Electrophoretic mobility shift assay Y639F/H784A/K378R T7 RNA
Polymerase
2 nM 42




Clone A5 Kd D 8.4 nM
Clone B4 Kd D 26 nM
43
Tissue factor pathway inhibitor Nitrocellulose membrane filter
binding
Not Specified ARC17480 Kd D 2.8 nM
ARC19499 IC50 D 17.9 nM
44
40-S Human thrombin Nitrocellulose membrane filter
binding
T7 RNA polymerase 4.7 nM 50
20-FANA HIV-1 reverse transcriptase Electrophoretic mobility shift assay Taq polymerase 4 pM 51
HNA TAR Magnetic bead immobilisation Pol6G12 28–67 nM 52
HIV Hen egg lysozyme Magnetic bead immobilisation Pol6G12 HNA11 Kd D 107 nM
HNA19 Kd D 141 nM
52
TNA Human thrombin Capillary electrophoresis Therminator DNA polymerase 200–900 nM 53
BNA/LNA Human thrombin Capillary electrophoresis an enzyme mix of KOD Dash
and KOD mutant DNA
polymerases
0.26–27 nM 23,70
CD73 Affinity column KOD XL 3.7 nM 22
Spiegelmers D-adenosine Affinity column T7 polymerase 1.7 mM 71
L-arginine Affinity column T7 polymerase Bound to L-arginine with
Kd D 129 mM
72
HIV-1 Tat protein Bound to HIV-1 tat protein
with KdD26 mM
D-vasopressin Electrophoretic mobility shift assay T7 polymerase 0.9 mM 73
D-staphylococcal enterotoxin B Electrophoretic mobility shift assay Taq DNA polymerase 200 nM 74
Nociceptin/ orphanin FQ Affinity column T7 polymerase L-NOX2149 Kd D 0.3 mM




Affinity column T7 polymerase L-S42 Kd D 45 nM
L-A10 Kd not specified
(IC50 D 200 nM)
78
Ghrelin Electrophoretic mobility shift assay T7 polymerase 44.4 nM 79,80
Calcitonin gene-related
peptide
Affinity column T7 polymerase Apparent Kd D 2.5 nM 75
Substance P Affinity column T7 polymerase 40 nM 76




































aptamers toward their targets. There are a few studies compar-
ing the two modifications to validate which modification was
more powerful. Kubik et al. reported an aptamer that bound to
interferon-gamma (IFN-g) which was screened from RNA
libraries modified at the 20-position of pyrimidine nucleotides
with F, NH2, or a mixture of F and NH2 (20-F/NH2) groups
using nitrocellulose filter binding assay.40 The binding affinity
of the modified aptamers to IFN-g differed depending on the
sugar modifications.40 20-NH2 modified aptamers had the high-
est binding affinity to IFN-g with a Kd of 1.8 nM, whereas the
20-F modified aptamers with the highest binding affinity had a
Kd of 6.8 nM and the aptamers containing 20-F/NH2 mixture
had a Kd of 106 nM.
40 The half-lives of these aptamers were
measured through their stability in human serum, where 20-
NH2 modified aptamer had a half-life of 80 h, 20-F modified
aptamers had a half-life of 6 h and the mixed 20F/NH2 modified
aptamers had a half-life of 48 h.40 However, all three were more
nuclease-resistant than the unmodified aptamer which had a
half-life of 20 s in human serum.40 20-NH2 modified aptamers
seemed to confer the highest binding affinity to IFN-g and
nuclease resistance in human serum.40 20-NH2 aptamer also
inhibited IFN-g binding to its receptor on A549 human lung
carcinoma cells with an ID50 of 10 nM.
40 Another study by
Pagratis et al. suggested that 20-F modified aptamers improved
the binding affinity compared to the 20-NH2 modified
aptamers.41 In this study, aptamers have been selected success-
fully from libraries containing 20-NH2 and 20-F modified pyri-
midines by nitrocellulose filter binding assay and compared the
affinities of the two different aptamer variants to keratinocyte
growth factor (KGF).41 The best 20-F modified aptamer 14F
bound to KGF with a higher affinity (Kd D 0.3–3 pM) than the
best 20-NH2 modified aptamer (Kd D 0.4 nM).41 20-F modified
aptamers (6F and 14F) inhibited KGF binding to their receptor
in PC3 cells with a Ki of 100 and 200 pM respectively and had a
much higher inhibitory activity than the 20-NH2 modified var-
iants, 14N and 29N (Ki D 1.4 nM).41 Although if 20-F or
20-NH2 modification is more powerful is arguable the use of
20-NH2 modifications result in problems in solid-phase synthe-
sis and the ribose sugar adopting an unfavorable conformation
which has resulted in the reduced use of 20-NH2.
20-OMe modifications:
20-OMe modification involves the replacement of the 20-OH
group of the nucleotide with a methoxy group. 20-OMe is a
common sugar modification that has been used post-SELEX to
generate aptamers with high nuclease resistance. Burmeister
et al. developed an aptamer against VEGF from oligonucleotide
libraries modified with 20-OMe adenine and guanines by elec-
trophoretic mobility shift assay.42 The selected aptamer candi-
date, ARC245 had a Kd of 2 nM, however this is lower than
Macugen, the FDA approved aptamer drug targeting VEGF
(Kd D 50 pM).42 ARC245 showed inhibition of VEGF binding
to VEGF receptor in 293 cells at 10 nM concentrations and was
also highly stable in serum for up to 96 h.42 Burmeister et al.
also screened aptamers comprising 20-OMe pyrimidines by the
SELEX process to multiple protein targets including thrombin
and interleukin-23, using proteins immobilized on a 96-well
plate and nitrocellulose filter binding assay.43 The identified
aptamers targeting interleukin-23 had a Kd of 8.4 nM while the
aptamer targeting thrombin had a Kd of 26 nM.
43 Waters et al.
developed 20-OMe modified aptamers, ARC19499 and
ARC17480 against tissue factor pathway inhibitor by nitrocel-
lulose filter binding using a 20-OMe modified library.44
ARC17480 bound to the tissue factor pathway inhibitor with a
Kd of 2.8 nM, however as ARC19499 was not viable in experi-
ments requiring radiolabelling a competition-binding experi-
ment showed that ARC19499 competed with radiolabelled
ARC17480 with an IC50 of 17.9 nM.
44 20-OMe incorporation
into libraries and using these modified libraries for SELEX is
hard due to lack of enzymes that are capable of recognizing
these 20-OMe modified bases. However, recently polymersases
have been evolved that accept 20-OMe modified triphosphates
which would allow generation of additional 20-OMe modified
aptamers.21,45-49
40-Thio (40-S) modifications
40-S modifications had a sulfur atom at the 40-position of the
sugar moiety. Kato et al. developed a 40-S modified RNA
aptamer that bound to human a-thrombin by nitrocellulose fil-
ter binding assay.50 In the presence of RNase, the stability of
the aptamer candidate, thioRNA59, had a half-life of 1174
mins and was stable even after 12 h of incubation, which was
50 times greater than that of the corresponding natural RNA
(completely degraded in the presence of RNase A in 3 h), and it
also showed high binding affinity to thrombin with a Kd of
4.7 nM.50
20-fluroarabino nucleic acid (20-FANA) modified aptamers
Very recently, Alves Ferreira-Bravo et al. reported a 20-FANA
aptamer to human immunodeficiency virus-1 (HIV-1) reverse
transcriptase.51 This 20-FANA aptamer was isolated from a 20-
FANA modified DNA pool through SELEX using electropho-
retic mobility shift assay.51 The developed 20-FANA modified
DNA aptamer, FA1 had a Kd value of 4 pM and showed greater
resistance to nucleases.51
1,5-anhydro hexitol nucleic acid (HNA) modified aptamers
Pinheiro et al. developed HNA aptamers against HIV-1 trans-
activation responsive element (TAR) and hen egg lysozyme
through SELEX using magnetic bead-based separation.52 HNA
aptamer, T5-S8-7 bound to TAR with high specificity and had
a Kd of 28–67 nM.
52 HNA aptamers that bound specifically to
hen egg lysozyme had a Kd of 107 to 141 nM as determined by
surface plasmon resonance.52
Threose nucleic acid (TNA) modified aptamers
Yu et al. selected a TNA modified aptamer against thrombin
using affinity column and capillary electrophoresis.53,54 TNA
backbone is nuclease-resistant as TNA remained undigested
even after 72 h of incubation with a pure nuclease unlike DNA
and RNA which exhibit half-lives of 30 mins and less than 10s
respectively.54 The developed TNA aptamers to thrombin had
a Kd in the range of 200–900 nM.





































independent TNA polymerase was evolved using droplet-based
optical polymerase sorting which can be used in TNA aptamer
selection protocol.55
Locked nucleic acid (LNA) modified aptamers
In LNA, the sugar ring is locked by a 20O, 40C methylene link-
age and is conformationally restricted adopting a C30-endo
conformation.56-61 Toward the development of LNA-modified
aptamers, Veedu et al. and others have extensively investigated
the enzymatic recognition capabilities of LNA-nucleotides.58-68
DNA aptamers containing LNA (BNA/LNA) nucleotides were
developed against human thrombin using capillary electropho-
resis SELEX. BNA/LNA-modified nucleotides were introduced
in the primer-binding region of the library, and after selection
the selected candidates were enriched by PCR using the LNA-
modified primer sequence to regenerate the selected aptamer
candidates using KOD polymerase.23,69 Many aptamers
showed Kd values in the low nanomolar range.
23,70 In
another study, Elle et al. generated LNA-modified aptamers
against CD73 immobilized on anti-His tag plates.22 A LNA-
modified DNA aptamer NAC6772 showed high binding
affinity to CD73 through surface plasmon resonance experi-
ment with a Kd of 3.54 nM and inhibited the CD73 activity
by 85%.22
Spiegelmers
Spiegelmers are mirror images of the natural aptamers in which
the D-ribose (the natural ribose) are replaced with the unnatu-
ral L-ribose. Spiegelmers prevent enzymatic degradation as the
chiral form of the nucleic acid (the L-form) is unnatural and is
not recognized by nucleases. However, the L-form of the
nucleic acid like their D-form natural counter parts can bind to
the target with high affinity and will not trigger the immune
response. Similar to the other sugar modifications described
above, spiegelmers can be enriched by T7 RNA polymerases.
Klussmann et al. generated one of the first spiegelmers through
SELEX against the naturally occurring D-adenosine.71 The high
affinity L-RNA aptamers against D-adenosine were isolated
through affinity column and had a Kd of 1.7 mM which was
comparable to the affinity displayed by the D-RNA aptamers.71
Nolte et al. reported another spiegelmer that bound to L-argi-
nine that could also bind to a short peptide that contains an
arginine-rich region in HIV-1 Tat protein.72 The aptamer, L-
R16c was isolated through affinity column based SELEX.72 L-
R16c bound to L-arginine with a Kd of 129 mM and to the Tat
protein with a Kd of 26 mM.
72 L-R16c was very stable in serum
and did not degrade even after 60 h of incubation.72 In another
study, spiegelmers were selected against D-vasopressin and D-
staphylococcal enterotoxin B through SELEX using electropho-
retic mobility shift assay.73 The L-DNA aptamers targeting D-
vasopressin showed no degradation with exo- and endonu-
cleases and showed high binding affinity for D-vasopressin
with a Kd of 0.9 mM.
73 The corresponding D-aptamer degraded
in 10 s while the L-aptamer showed no degradation even after
10 days incubation with exo- and endonucleases and 7 days in
serum.73 A DNA spiegelmer targeting D-staphylococcal entero-
toxin B, B12b10 had a Kd of 200 nM.
74 Vater et al. isolated a
RNA spiegelmer against migraine associated calcitonin gene-
related peptide through SELEX using affinity columns.75 The
developed RNA spiegelmer STAR-F12 bound to calcitonin
gene-related peptide with a Kd of 2.5 nM and inhibits its activ-
ity.75 In another study, a RNA spiegelmer targeting Substance
P was generated through SELEX using affinity column.76 The
developed L-RNA aptamer, SUP-A-004, which was further
truncated and the resulting spiegelmer bound to Substance P
with a Kd of 40 nM.
76 SUP-A-004 inhibited L-substance P
mediated Ca2C release in AR42J pancreatic cells.76 Faulhammer
et al., in another study reported the development of L-RNA
aptamers NOX2149 and NOX2137 against Nociceptin/orpha-
nin FQ through SELEX using affinity column.77 The L-
NOX2149 and L-NOX2137 bound to the nociception/orphanin
FQ with a Kd of 0.3 mM and 0.7 mM respectively which were
similar to the binding affinity to their D-aptamer counter-
parts.77 However L-aptamers had the advantage of being more
stable in serum.77 In another study, L-DNA/RNA aptamers
that bind to D-gonadotropin-releasing hormone with high
affinity and specificity were isolated out of L-RNA and DNA
libraries through SELEX using affinity column.78 The L-DNA
aptamer, S42 bound to gonadotropin-releasing hormone with a
Kd of 45 nM which is similar to that of the D-DNA aptamer
and the IC50 was 50 nM.
78 The D-RNA aptamer, A10 bound
with Kd of 55 nM, however the Kd of L-RNA aptamer could
not be obtained.78 Both the DNA and RNA spiegelmers bound
to gonadotropin-releasing hormones and inhibited their bind-
ing to their receptor in Chinese hamster ovary cells and there
was no immune response produced in zimmermann rabbits.78
Helming et al. reported L-RNA aptamers targeting ghrelin
through SELEX using electrophoretic mobility shift assay.79,80
L-NOX-B11, a L-RNA aptamer was isolated and bound to
ghrelin with high affinity with a Kd of 44.4 nM.
80 L-NOX-B11
inhibited ghrelin from binding to its receptor with an IC50
value of 5 nM in Chinese hamster ovary cells.79,80 NOXXON
Pharma have developed many spiegelmers against various tar-
gets and a few of the spiegelmers are in various stages of the
preclinical and clinical trials, two of which are described in a
recent review by Sundaram et al. NOX-A12 is a spiegelmer that
bound to and inhibits stroma cell-derived factor-1.81 After
completion of Phase I and Phase IIa trials of NOX-A12, Phase
3 trials have been planned for multiple myeloma.81 Also, Phase
2b/3 trials have been planned for the same candidate against
glioblastoma.81 Phase 2a clinical trials have been completed for
another spiegelmer, NOX-E36, targeting monocyte chemoat-
tractant- protein 1.81 Several other candidates are currently in
different stages of clinical investigation.82 NOX-D20 is another
spiegelmer that binds to anaphylatoxin C5a with picomolar
affinity and is being considered for preclinical and clinical
development.83 Wang et al. has described the generation of a
chemically-synthesized D-amino acid polymerase that is capa-
ble of recognizing and catalyzing transcription and polymerisa-
tion of an L-DNA template.84 This polymerase could result in
generation of new speigelmers in the future.84
Aptamer selection using modified nucleotide bases
Incorporating chemical modification to the nucleotide bases
could increase the stability and target-binding affinity of




































aptamers. A number of researchers have succeeded in generat-
ing aptamers with base-modified nucleotides (Fig. 4), some of
which are in preclinical stages. Various base modifications are
incorporated into the nucleic acid library and in many cases
have been able to be amplified using family B-DNA polymer-
ases.85 Table 2 provides a summary of base-modified aptamer
development. There is also a new method called click-SELEX
which is used to generate base-modified libraries by replacing
the thymidines with C5-ethynyl-20-deoxyuridine which is then
further modified through click reaction with copper(I)-
catalyzed alkyne-azide cycloaddition.86-91 The library is then
used in selection experiments to evolve modified aptamers.86-91
This is a powerful method that allows generation of modified
aptamers with new chemical modifications without problems
caused by lack of enzymatic recognition as seen with the addi-
tion of a cluster of oligomannose glycans.86-91 This will allow
targeting of many molecules and epitopes that is currently not
possible with standard SELEX.86-91 Addition of new nucleotides
and/or unnatural base pairs to the libraries and using these
libraries for aptamer selection allows generation of modified





































aptamers with greater sequence and functional diversity.92-95
Zhang et al. has shown that addition of new nucleotides Z and
P allowed generation of sequences that had better binding affin-
ity to the target molecule indicating that new nucleotides are
viable in the library and can show higher binding affinity than
natural bases in some cases.92
Uridine modifications
Latham et al. developed a modified aptamer containing 5-(1-
pentynyl)-20-deoxyuridine against thrombin by affinity col-
umn.96 The affinity of the selected aptamer pool was 400 nM.96
This was one of the first examples of using a base-modified
nucleic acid library for screening aptamers. In another study,
Jensen et al. developed RNA aptamers from a random RNA
library containing photoreactive chromophore 5-iodouridine
using crosslinking SELEX.97 The selected RNA aptamers bound
and also cross-linked to the target with UV irradiation.97 These
modified aptamers had high affinity with a Kd of 0.8 nM.
97
Battersby et al. isolated another base-modified aptamer contain-
ing 5-aminopropynyl-deoxyuridine against ATP by electropho-
retic mobility shift assay.98,99 One of the selected aptamer
candidate, 409 was found to bind ATP with higher affinity
(Kd D 6 mM) than their unmodified counterparts.98,99 Shoji et al.
reported another base-modified aptamer with 50-N-6-NH2-hexyl
carbamoylmethyl dU.100,101 The modified library was used to
screen aptamers against thalidomide using streptavidin-sepharose
gel.100 Surface plasmon resonance showed that the selected
base-modified aptamer T5N and T51B had a Kd of 113 mM and
133 mM respectively.100 Li et al. selected an aptamer containing
boronic acid-modified thymidine against fibrinogen using
magnetic bead immobilization-based SELEX.102 The resulting
modified aptamers bound to fibrinogen with high affinity
compared to that of the unmodified aptamers (Kd D 3–30 nM
compared to Kd D 450 nM).102 Vaught et al. selected a DNA
aptamer against tumor necrosis factor receptor super family 9
from a library possessing 5-amide-modified deoxyuridine via a
magnetic bead-based SELEX method.103 Six 5-position modified
20-dUTP derivatives were used.103 Two of the modified DNA
aptamers developed showed high affinity (Kd D 6 nM and 4 nM
respectively) compared to an unmodified RNA aptamer that has
been previously reported (Kd D 40 nM).103
Imidazole modifications
Aptamers can also act as DNA enzymes which are catalytic
nucleic acids and modified libraries have been used to select
such aptamers. Sontoro et al. developed a modified DNAzyme
aptamer via affinity column from a modified library containing
C5-imidazole-functionalised dU.104 The isolated DNAzyme
was one of the smallest nucleic acid enzymes, which showed
multiple turnovers in the presence of millimolar concentrations
of Zn2C, and a catalytic rate of 1.4–1.5 min¡1 for cleavage.104
Kimoto et al. reported the selection of 7-(2-thienyl)imidazole
Table 2. Aptamers selected from base-modified DNA/RNA libraries and the binding affinity of aptamers to their targets.
Modified nucleotide Target Selection Method Polymerases Used Binding affinity (Kd) Ref.
5-pentynyl-dU Human thrombin Affinity column Vent DNA Polymerase 400 nM 96
5-N-(6-aminohexyl) carbamoylmethyl-dU Thalidomide (T5N and T5-IB) Streptavidin-sepharose gel KOD Dash DNA
polymerase
T5N KdD 113 mM
T5-1B KdD 133 mM
100
5-boronic acid-dT Fibrinogen Magnetic bead
immobilisation
Taq DNA Polymerase 3–30 nM 102
5-iodouridine HIV-1 Rev protein. Nitrocellulose membrane
filter binding
T7 RNA polymerase 0.8 nM 97
5-(30-aminopropynyl)-20-dU ATP (Sequence 409) Capillary electrophoresis Vent DNA polymerase 6 nM 98




KOD DNA Polymerase 30 nM 107
5-isobutylaminocarbonyl –dU Human mobility group -1 30 nM
5-tryptaminocarbonyl -dU Fractalkine 30 nM













7-(2-thienyl)imidazo[4,5-b]pyridine VEGF165 Magnetic bead
immobilisation




5-tyrosyl-dU Clostridium difficile binary
toxins A and B
Magnetic bead
immobilisation
KOD EX DNA polymerase 1.4 nM (Toxin A)
0.31 nM (Toxin B)
109
5-(2-naphthylmethylaminocarbonyl)-dU 9.2 nM (Toxin A)
0.25 nM (Toxin B)
5-phenylethyl-dU 13.1 nM (Toxin A)
0.27 nM (Toxin B)
5-benzylaminocarbonyl-dU 5 nM (Toxin B)
5-naphthylmethylaminocarbonyl-dU 0.43 nM (Toxin B)
5-tryptaminocarbonyl-dU 1.7 nM (Toxin A)
0.45 nM (Toxin B)
5-carboxamide-modified-dU Tumor necrosis factor
receptor super family
member 9 (6a and 6d)
Magnetic bead
immobilisation
Deep Vent and KOD XL
DNA Polymerases
6a KdD 6 nM
6d KdD 4 nM
103








































[4,5-b]pyridine modified DNA aptamers against VEGF165 and
IFN-g by magnetic bead-based SELEX.105 The isolated DNA
aptamers bound to VEGF165 and IFN-g with 100 fold higher
affinity than their natural counterparts with Kd values of 0.64
pM and 0.038 nM respectively.105 Hollenstein et al. reported
the development of Dz12–91, a modified DNAzyme containing
imidazole, ammonium and guanidinium groups. Dz12–91 was
isolated through SELEX using magnetic streptavidin particles
and cleaves all RNA sequence independently of M2C with a
Kobs of 0.06 min
¡1.106
Slow off-rate modified aptamers (SOMAmers)
Another class of aptamers with improved binding properties
through base-modifications that result in slow dissociation rates
called SOMAmers. There are many SOMAmer modifications
that are used to generate aptamers to difficult protein targets.107
The affinities of the SOMAmers are consistently in the nanomo-
lar range to their targets and show high nuclease resistance.107
Various proteins have been used as targets to generate
SOMAmers.107,108 In many SOMAmers, the modifications are
introduced at the 5-position of the uridine nucleotide.107 Gold
et al. described the development of SOMAmers against more
than 800 targets using multiplex SOMAmer affinity assay system
from base-modified libraries including 5-benzylaminocarbonyl,
5-naphthylmethylaminocarbonyl, 5-tryptaminocarbonyl, 5-isobu-
tylaminocarbonyl, 5-tyrosyl, 5-phenylethyl, and 5-guanidi-
noallyl.107,109 Ochsner et al. reported development of SOMAmers
against toxins A, B and binary toxins using 5-benzylaminocar-
bonyl, 5-naphthylmethylaminocarbonyl, 5-tryptaminocarbonyl,
5-phenylethyl-1-aminocarbonyl, 5-tyrosylaminocarbonyl or 5-(2-
naphthylmethyl)aminocarbonyl-modified uridine containing
library using magnetic bead-based SELEX.109 Most of the modi-
fied aptamers bound to the toxin A and B with high binding
affinity with the Kd in the nanomolar range.
109 For example, the
selected 5-tryptaminocarbonyl dU modified aptamer showed a
Kd of 1.7 nM to Toxin A and 0.45 nM for Toxin B.
109
Aptamer selection using phosphate modified
nucleotides
A few phosphate-modified aptamers (Fig. 5) were reported as
substrates of T7 RNA polymerase that could accept the triphos-
phate analogs of the modified phosphate moiety, mainly phos-
phorothioate and boranophosphates. Table 3 provides a
summary of base-modified aptamer development.
Phosphorothioate modifications
Through nitrocellulose membrane filter binding, phospho-
thioate-modifed RNA aptamer 11–20 was isolated that bound
to bFGF with a Kd of 1.8 nM which was similar to the Kd of all
RNA aptamers (Kd D 0.19 nM and 0.49 nM).110 Kd of another
bFGF aptamer containing 20-NH2 pyrimidines was 0.35 nM,
which was also comparable to the unmodified RNA
aptamers.110 These aptamers also bound to other bFGF mem-
bers in the family, but not to the unrelated targets and were
therefore “semi-specific” for the FGF family members.110
Another phosphorothioate DNA aptamer was selected against
nuclear factor for human interleukin 6 which was nuclease-
resistant to DNase 1 enzyme at the point of modifications.111,112
This modified DNA aptamer was selected through nitrocellu-
lose filter binding from a library with thiophosphate backbone
substitution at the thymidine positions and the modified
aptamer was found to bind with stoichemistry of two protein
dimers/duplex unlike the unmodified aptamer which bound
with one protein dimer/duplex stoichemistry.112 The binding
constant (Kobs) measured by fluorescence anisotropy was 2 nM
Figure 5. Structures of various phosphate-modified nucleotides used in aptamer selection by SELEX methodologies.
Table 3. Aptamers selected from phosphate-modified DNA/RNA libraries and the binding affinity of aptamers to their targets.
Modified nucleotide Target Selection Method Polymerases Used Binding affinity (Kd) Ref.
Boranophosphate-50-(a-P-borano)-G
50-(a-P-borano)-U
ATP Affinity column T7 RNA Polymerase Not Specified 113
Phosphorothioate-modified DNA bFGF Nitrocellulose membrane
filter binding
Taq polymerase 1.8 nM 110
Phosphorothioate-dA Nuclear factor for human Interleukin6 Nitrocellulose membrane
filter binding
Taq DNA Polymerase Kd not specified
(Kobs D 2 nM)
112




Taq DNA Polymerase 4.8 nM 111







































for a 66-mer.112 Another phosphorothioate aptamer was
selected against Nuclear Factor kappa B proteins Rel A (p65)
and p50 and the selected aptamer had a Kd value of 4.8 nM and
0.8 nM respectively, which was comparable to the unmodified
aptamer (Kd D 4.77 nM).111
Boranophosphate modification
Boronated nucleotide analog modifications of guanosine (50(a-P-
borano)triphosphate) for GTP and uridine (50(a-P-borano)
triphosphate) for UTP were also introduced into general librar-
ies to select modified aptamers that bind ATP through affinity
matrix containing C8-linked ATP agarose.113 Each of the 2 mod-
ifications were tolerated in the backbone alone, however both
modifications in one backbone were not tolerated.113
Conclusions and future perspectives
Aptamers are nucleic acid ligands that are generally developed
through SELEX and bind to their targets with high affinity and
specificity. Aptamers can be used therapeutically, diagnostically,
as molecular beacons or as DNAzymes in various diseases.
Macugen is a therapeutic aptamer approved by the US FDA for
the treatment of AMD. One of the major disadvantages of
aptamers composed of natural nucleotides is their rapid
degradation in vivo. To overcome this obstacle, chemically-modi-
fied aptamers have been developed through SELEX using
modified-oligonucleotide libraries. There are many potential
chemically-modified nucleotides with excellent properties, how-
ever many of them cannot be used in the SELEX processes to
develop aptamers mainly because of their very limited enzymatic
recognition capabilities which are required for enrichment steps.
As reviewed here, it is very promising to see the development of
chemically-modified aptamers using several sugar, base and
phosphate-modified nucleotides. It is also very encouraging to
note the development of novel engineered polymerases capable
of recognizing a specific modified nucleotide. Recent develop-
ments in one-step-based selection methodologies further offer
tremendous hope for developing aptamers containing modified
aptamers with limited enzymatic recognition capabilities.
Disclosure of potential conflicts of interest
No potential conflicts of interest were disclosed.
Acknowledgment
RNV acknowledges the funding from McCusker Charitable Foundation,
and Western Australian Neuroscience Research Institute. MC thanks the




1. Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev
Drug Discov 2010; 9:537-50; PMID:20592747; http://dx.doi.org/
10.1038/nrd3141
2. Nimjee SM, Rusconi CP, Sullenger BA. Aptamers: an emerging class
of therapeutics. Annu Rev Med 2005; 56:555-83; PMID:15660527;
http://dx.doi.org/10.1146/annurev.med.56.062904.144915
3. Famulok M, Hartig JS, Mayer G. Functional aptamers and aptazymes
in biotechnology, diagnostics, and therapy. Chem Rev 2007;
107:3715-43; PMID:17715981; http://dx.doi.org/10.1021/cr0306743
4. Veedu RN. Editorial (Thematic Issue: Medicinal Chemistry of
Aptamers). Curr Top Med Chem 2015; 15:1065; PMID:25866280;
http://dx.doi.org/10.2174/1568026615666150413161707
5. Jayasena SD. Aptamers: an emerging class of molecules that rival
antibodies in diagnostics. Clin Chem 1999; 45:1628-50;
PMID:10471678
6. Stoltenburg R, Reinemann C, Strehlitz B. SELEX—a (r) evolutionary
method to generate high-affinity nucleic acid ligands. Biomol Eng
2007; 24:381-403; PMID:17627883; http://dx.doi.org/10.1016/j.
bioeng.2007.06.001
7. Gopinath SCB. Methods developed for SELEX. Anal Bioanal Chem
2007; 387:171-82; PMID:17072603; http://dx.doi.org/10.1007/
s00216-006-0826-2
8. Demarest SJ, Glaser SM. Antibody therapeutics, antibody engineer-
ing, and the merits of protein stability. Curr Opin Drug Discov Devel
2008; 11:675-87; PMID:18729019
9. Ng EWM, Shima DT, Calias P, Cunningham ET, Guyer DR, Adamis
AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular
disease. Nat Rev Drug Discov 2006; 5:123-32; PMID:16518379;
http://dx.doi.org/10.1038/nrd1955
10. Group MDRS. A phase II randomized double-masked trial of pegap-
tanib, an anti–vascular endothelial growth factor aptamer, for dia-
betic macular edema. Ophthalmology 2005; 112:1747-57;
PMID:16154196; http://dx.doi.org/10.1016/j.ophtha.2005.06.007
11. Kanwar JR, Roy K, Maremanda NG, Subramanian K, Veedu RN, Bawa
R, Kanwar RK. Nucleic acid-based aptamers: applications, development
and clinical trials. Curr Med Chem 2015; 22:2539-57; PMID:25723512;
http://dx.doi.org/10.2174/0929867322666150227144909
12. Zuker M. Mfold web server for nucleic acid folding and hybridiza-
tion prediction. Nucleic Acids Res 2003; 31:3406-15;
PMID:12824337; http://dx.doi.org/10.1093/nar/gkg595
13. Hofacker IL. Vienna RNA secondary structure server. Nucleic Acids
Res 2003; 31:3429-31; PMID:12824340; http://dx.doi.org/10.1093/
nar/gkg599
14. Diafa S, Hollenstein M. Generation of aptamers with an expanded
chemical repertoire. Molecules 2015; 20:16643-71; PMID:26389865;
http://dx.doi.org/10.3390/molecules200916643
15. Dellafiore MA, Montserrat JM, Iribarren AM. Modified Nucleoside
Triphosphates for In-vitro Selection Techniques. Front Chem 2016;
4:18; PMID:27200340; http://dx.doi.org/10.3389/fchem.2016.00018
16. Kong D, Yeung W, Hili R. Generation of Synthetic Copolymer
Libraries by Combinatorial Assembly on Nucleic Acid Templates.
ACS Comb Sci 2016; 18:355-70; PMID:27275512; http://dx.doi.org/
10.1021/acscombsci.6b00059
17. Lapa SA, Chudinov AV, Timofeev EN. The toolbox for modified
aptamers. Mol Biotechnol 2016; 58:79-92; PMID:26607475; http://
dx.doi.org/10.1007/s12033-015-9907-9
18. Rohloff JC, Gelinas AD, Jarvis TC, Ochsner UA, Schneider DJ, Gold
L, Janjic N. Nucleic acid ligands with protein-like side chains: modi-
fied aptamers and their use as diagnostic and therapeutic agents. Mol
Ther Nucleic Acids 2014; 3:e201; PMID:25291143; http://dx.doi.org/
10.1038/mtna.2014.49
19. Lauridsen LH, Rothnagel JA, Veedu RN. Enzymatic recognition of
20modified ribonucleoside 50triphosphates: Towards the evolu-
tion of versatile aptamers. ChemBioChem 2012; 13:19-25;
PMID:22162282; http://dx.doi.org/10.1002/cbic.201100648
20. Loakes D, Holliger P. Polymerase engineering: towards the encoded
synthesis of unnatural biopolymers. Chem Commun 2009:4619-31;
PMID:19641798; http://dx.doi.org/10.1039/b903307f




































21. Aschenbrenner J, Marx A. Direct and site-specific quantification of
RNA 20-O-methylation by PCR with an engineered DNA polymer-
ase. Nucleic Acids Res 2016; 44:3495-502; PMID:27016740; http://
dx.doi.org/10.1093/nar/gkw200
22. Elle IC, Karlsen KK, Terp MG, Larsen N, Nielsen R, Derbyshire
N, Mandrup S, Ditzel HJ, Wengel J. Selection of LNA-containing
DNA aptamers against recombinant human CD73. Mol Biosyst
2015; 11:1260-70; PMID:25720604; http://dx.doi.org/10.1039/
C5MB00045A
23. Kasahara Y, Irisawa Y, Ozaki H, Obika S, Kuwahara M. 20, 40-BNA/
LNA aptamers: CE-SELEX using a DNA-based library of full-length
20-O, 40-C-methylene-bridged/linked bicyclic ribonucleotides. Bioorg
Med Chem Lett 2013; 23:1288-92; PMID:23374873; http://dx.doi.
org/10.1016/j.bmcl.2012.12.093
24. Lauridsen LH, Shamaileh HA, Edwards SL, Taran E, Veedu RN.
Rapid one-step selection method for generating nucleic acid
aptamers: Development of a DNA aptamer against a-bungarotoxin.
PLoS One 2012; 7:e41702; PMID:22860007; http://dx.doi.org/
10.1371/journal.pone.0041702
25. Nitsche A, Kurth A, Dunkhorst A, P€anke O, Sielaff H, Junge W,
Muth D, Scheller F, St€ocklein W, Dahmen C et al. One-step selection
of Vaccinia virus-binding DNA aptamers by MonoLEX. BMC Bio-
technol 2007; 7(1):48; PMID:17199888; http://dx.doi.org/10.1186/
1472-6750-7-48
26. Peng L, Stephens BJ, Bonin K, Cubicciotti R, Guthold M. A com-
bined atomic force/fluorescence microscopy technique to select
aptamers in a single cycle from a small pool of random oligonucleoti-
des. Microsc Res Tech 2007; 70:372-81; PMID:17262788; http://dx.
doi.org/10.1002/jemt.20421
27. Fan M, McBurnett SR, Andrews CJ, Allman AM, Bruno JG, Kiel JL.
Aptamer selection express: a novel method for rapid single-step
selection and sensing of aptamers. J Biomol Tech 2008; 19:311;
PMID:19183794
28. Lin Y, Qiu Q, Gill SC, Jayasena SD. Modified RNA sequence pools
for in vitro selection. Nucleic Acids Res 1994; 22:5229-34;
PMID:7529404; http://dx.doi.org/10.1093/nar/22.24.5229
29. Green LS, Jellinek D, Bell C, Beebe LA, Feistner BD, Gill SC, Jucker FM,
Janjic N. Nuclease-resistant nucleic acid ligands to vascular permeability
factor/vascular endothelial growth factor. Chem Biol 1995; 2:683-95;
PMID:9383475; http://dx.doi.org/10.1016/1074-5521(95)90032-2
30. Beaudry A, DeFoe J, Zinnen S, Burgin A, Beigelman L. In vitro selec-
tion of a novel nuclease-resistant RNA phosphodiesterase. Chem
Biol 2000; 7:323-34; PMID:10801472; http://dx.doi.org/10.1016/
S1074-5521(00)00110-1
31. Jellinek D, Green LS, Bell C, Lynott CK, Gill N, Vargeese C,
Kirschenheuter G, McGee DP, Abesinghe P. Potent 20-amino-20-
deoxypyrimidine RNA inhibitors of basic fibroblast growth factor.
Biochemistry 1995; 34:11363-72; PMID:7547864; http://dx.doi.org/
10.1021/bi00036a009
32. Bugaut A, Toulme J-J, Rayner B. SELEX and dynamic combinatorial
chemistry interplay for the selection of conjugated RNA aptamers.
Org Biomol Chem 2006; 4:4082-8; PMID:17312962; http://dx.doi.
org/10.1039/b610890c
33. Ruckman J, Green LS, Beeson J, Waugh S, Gillette WL, Henninger
DD, Claesson-Welsh L, Janjic N. 20-Fluoropyrimidine RNA-based
aptamers to the 165-amino acid form of vascular endothelial growth
factor (VEGF165). Inhibition of receptor binding and VEGF-
induced vascular permeability through interactions requiring the
exon 7-encoded domain. J Biol Chem 1998; 273:20556-67;
PMID:9685413; http://dx.doi.org/10.1074/jbc.273.32.20556
34. Lupold SE, Hicke BJ, Lin Y, Coffey DS. Identification and characteri-
zation of nuclease-stabilized RNA molecules that bind human pros-
tate cancer cells via the prostate-specific membrane antigen. Cancer
Res 2002; 62:4029-33; PMID:12124337; http://dx.doi.org/10.1158/
0008-5472.can-12-2152
35. McNamara JO, Andrechek ER, Wang Y, Viles KD, Rempel RE,
Gilboa E, Sullenger BA, Giangrande PH. Cell type–specific delivery
of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006;
24:1005-15; PMID:16823371; http://dx.doi.org/10.1038/nbt1223
36. Biesecker G, Dihel L, Enney K, Bendele RA. Derivation of RNA
aptamer inhibitors of human complement C5. Immunopharmacol-
ogy 1999; 42:219-30; PMID:10408383; http://dx.doi.org/10.1016/
S0162-3109(99)00020-X
37. Layzer JM, Sullenger BA. Simultaneous generation of aptamers to
multiple gamma-carboxyglutamic acid proteins from a focused
aptamer library using DeSELEX and convergent selection. Oligonu-
cleotides 2007; 17:1-11; PMID:17461758; http://dx.doi.org/10.1089/
oli.2006.0059
38. Rusconi CP, Scardino E, Layzer J, Pitoc GA, Ortel TL, Monroe D,
Sullenger BA. RNA aptamers as reversible antagonists of coagulation
factor IXa. Nature 2002; 419:90-4; PMID:12214238; http://dx.doi.
org/10.1038/nature00963
39. Lamberti I, Scarano S, Esposito CL, Antoccia A, Antonini G,
Tanzarella C, De Franciscis V, Minunni M. In vitro selection of RNA
aptamers against CA125 tumor marker in ovarian cancer and its
study by optical biosensing. Methods 2016; 97:58-68;
PMID:26542762; http://dx.doi.org/10.1016/j.ymeth.2015.10.022
40. Kubik MF, Bell C, Fitzwater T, Watson SR, Tasset DM. Isolation and
characterization of 20-fluoro-, 20-amino-, and 20-fluoro-/amino-mod-
ified RNA ligands to human IFN-gamma that inhibit receptor bind-
ing. J Immunol 1997; 159:259-67; PMID:9200462
41. Pagratis NC, Bell C, Chang Y-F, Jennings S, Fitzwater T, Jellinek D,
Dang C. Potent 20-amino-, and 20-fluoro-20-deoxyribonucleotide
RNA inhibitors of keratinocyte growth factor. Nat Biotechnol 1997;
15:68-73; PMID:9035109; http://dx.doi.org/10.1038/nbt0197-68
42. Burmeister PE, Lewis SD, Silva RF, Preiss JR, Horwitz LR,
Pendergrast PS, McCauley TG, Kurz JC, Epstein DM, Wilson C.
Direct in vitro selection of a 20-O-methyl aptamer to VEGF.
Chem Biol 2005; 12:25-33; PMID:15664512; http://dx.doi.org/
10.1016/j.chembiol.2004.10.017
43. Burmeister PE, Wang C, Killough JR, Lewis SD, Horwitz LR,
Ferguson A, Thompson KM, Pendergrast PS, McCauley TG, Kurz
M. 2-Deoxy purine, 2-O-methyl pyrimidine (dRmY) aptamers as
candidate therapeutics. Oligonucleotides 2006; 16:337-51;
PMID:17155909; http://dx.doi.org/10.1089/oli.2006.16.337
44. Waters EK, Genga RM, Schwartz MC, Nelson JA, Schaub RG, Olson
KA, Kurz JC, McGinness KE. Aptamer ARC19499 mediates a pro-
coagulant hemostatic effect by inhibiting tissue factor pathway inhib-
itor. Blood 2011; 117:5514-22; PMID:21389323; http://dx.doi.org/
10.1182/blood-2010-10-311936
45. Chelliserrykattil J, Ellington A. Evolution of a T7 RNA polymerase
variant that transcribes 20-O-methyl RNA. Nat Biotechnol 2004;
22:1155-60; PMID:15300257; http://dx.doi.org/10.1038/nbt1001
46. Fa M, Radeghieri A, Henry AA, Romesberg FE. Expanding the sub-
strate repertoire of a DNA polymerase by directed evolution. J Am
Chem Soc 2004; 126:1748-54; PMID:14871106; http://dx.doi.org/
10.1021/ja038525p
47. Siegmund V, Santner T, Micura R, Marx A. Screening mutant librar-
ies of T7 RNA polymerase for candidates with increased acceptance
of 20-modified nucleotides. Chem Commun 2012; 48:9870-2;
PMID:22932771; http://dx.doi.org/10.1039/c2cc35028a
48. Padilla R, Sousa R. A Y639F/H784A T7 RNA polymerase double
mutant displays superior properties for synthesizing RNAs with non-
canonical NTPs. Nucleic Acids Res 2002; 30:e138-e;
PMID:12490729; http://dx.doi.org/10.1093/nar/gnf138
49. Wu Y, Sefah K, Liu H, Wang R, Tan W. DNA aptamer–micelle as an
efficient detection/delivery vehicle toward cancer cells. Proc Natl
Acad Sci 2010; 107:5-10; PMID:20080797; http://dx.doi.org/10.1073/
pnas.0909611107
50. Kato Y, Minakawa N, Komatsu Y, Kamiya H, Ogawa N, Harashima
H, Matsuda A. New NTP analogs: the synthesis of 40-thioUTP and
40-thioCTP and their utility for SELEX. Nucleic Acids Res 2005;
33:2942-51; PMID:15914669; http://dx.doi.org/10.1093/nar/gki578
51. Ferreira-Bravo IA, Cozens C, Holliger P, DeStefano JJ. Selection of
20-deoxy-20-fluoroarabinonucleotide (FANA) aptamers that bind
HIV-1 reverse transcriptase with picomolar affinity. Nucleic Acids






































52. Pinheiro VB, Taylor AI, Cozens C, Abramov M, Renders M,
Zhang S, Chaput JC, Wengel J, Peak-Chew S-Y, McLaughlin SH.
Synthetic genetic polymers capable of heredity and evolution.
Science 2012; 336:341-4; PMID:22517858; http://dx.doi.org/
10.1126/science.1217622
53. Yu H, Zhang S, Chaput JC. Darwinian evolution of an alternative
genetic system provides support for TNA as an RNA progenitor. Nat
Chem 2012; 4:183-7; PMID:22354431; http://dx.doi.org/10.1038/
nchem.1241
54. Yu H, Zhang S, Dunn MR, Chaput JC. An efficient and faithful in
vitro replication system for threose nucleic acid. J Am Chem Soc
2013; 135:3583-91; PMID:23432469; http://dx.doi.org/10.1021/
ja3118703
55. Larsen AC, Dunn MR, Hatch A, Sau SP, Youngbull C, Chaput JC. A
general strategy for expanding polymerase function by droplet
microfluidics. Nat Commun 2016; 7:11235; PMID:27044725; http://
dx.doi.org/10.1038/ncomms11235
56. Veedu RN, Vester B, Wengel J. In vitro incorporation of LNA
nucleotides. Nucleosides Nucleotides Nucleic Acids 2007; 26:1207-
10; PMID:18058567; http://dx.doi.org/10.1080/15257770701527844
57. Veedu RN, Vester B, Wengel J. Novel applications of locked nucleic
acids. Nucleic Acids Symp Ser: Oxford Univ Press, 2007; 51(1):29-
30; PMID:18029570; http://dx.doi.org/10.1093/nass/nrm015
58. Veedu RN, Vester B, Wengel J. Enzymatic incorporation of LNA
nucleotides into DNA strands. ChemBioChem 2007; 8:490-2;
PMID:17315250; http://dx.doi.org/10.1002/cbic.200600501
59. Veedu RN, Vester B, Wengel J. Polymerase chain reaction and tran-
scription using locked nucleic acid nucleotide triphosphates. J Am
Chem Soc 2008; 130:8124-5; PMID:18533656; http://dx.doi.org/
10.1021/ja801389n
60. Veedu RN, Vester B, Wengel J. Efficient enzymatic synthesis of LNA-
modified DNA duplexes using KOD DNA polymerase. Org Biomol
Chem 2009; 7:1404-9; PMID:19300826; http://dx.doi.org/10.1039/
b819946a
61. Veedu RN, Wengel J. Locked nucleic acid nucleoside triphosphates
and polymerases: on the way towards evolution of LNA aptamers.
Mol Biosyst 2009; 5:787-92; PMID:19603111; http://dx.doi.org/
10.1039/b905513b
62. Veedu RN, Wengel J. Locked nucleic acids: promising nucleic acid
analogs for therapeutic applications. Chem Biodivers 2010; 7:536-42;
PMID:20232325; http://dx.doi.org/10.1002/cbdv.200900343
63. Veedu RN, Wengel J. Locked nucleic acid as a novel class of thera-
peutic agents. RNA Biol 2009; 6:321-3; PMID:19458498; http://dx.
doi.org/10.4161/rna.6.3.8807
64. Crouzier L, Dubois C, Edwards SL, Lauridsen LH, Wengel J, Veedu
RN. Efficient reverse transcription using locked nucleic acid nucleoti-
des towards the evolution of nuclease resistant RNA aptamers. PLoS
One 2012; 7:e35990; PMID:22558297; http://dx.doi.org/10.1371/
journal.pone.0035990
65. Højland T, Veedu RN, Vester B, Wengel J. Enzymatic synthesis of
DNA strands containing a-L-LNA (a-L-configured locked nucleic
acid) thymine nucleotides. Artif DNA PNA XNA 2012; 3:14-21;
PMID:22679529; http://dx.doi.org/10.4161/adna.19272
66. Johannsen MW, Veedu RN, Madsen AS, Wengel J. Enzymatic poly-
merisation involving 20-amino-LNA nucleotides. Bioorg Med Chem
Lett 2012; 22:3522-6; PMID:22503454; http://dx.doi.org/10.1016/j.
bmcl.2012.03.073
67. Veedu RN, Vester B, Wengel J. Polymerase directed incorporation
studies of LNA-G nucleoside 50-triphosphate and primer extension
involving all four LNA nucleotides. New J Chem 2010; 34:877-9;
http://dx.doi.org/10.1039/b9nj00628a
68. Wheeler M, Chardon A, Goubet A, Morihiro K, Tsan SY, Edwards
SL, Kodama T, Obika S, Veedu RN. Synthesis of selenomethylene-
locked nucleic acid (SeLNA)-modified oligonucleotides by polymer-
ases. Chem Commun 2012; 48:11020-2; PMID:23042489; http://dx.
doi.org/10.1039/c2cc36464f
69. Kuwahara M, Obika S, Nagashima J-i, Ohta Y, Suto Y, Ozaki H,
Sawai H, Imanishi T. Systematic analysis of enzymatic DNA poly-
merization using oligo-DNA templates and triphosphate analogs
involving 20, 40-bridged nucleosides. Nucleic Acids Res 2008;
36:4257-65; PMID:18583360; http://dx.doi.org/10.1093/nar/gkn404
70. Kasahara Y, Irisawa Y, Fujita H, Yahara A, Ozaki H, Obika S,
Kuwahara M. Capillary electrophoresis–systematic evolution of
ligands by exponential enrichment selection of base- and sugar-
modified DNA aptamers: target binding dominated by 20-O, 40-C-
methylene-bridged/locked nucleic acid primer. Anal Chem 2013;
85:4961-7; PMID:23662585; http://dx.doi.org/10.1021/ac400058z
71. Klussmann S, Nolte A, Bald R, Erdmann VA, F€urste JP. Mirror-
image RNA that binds D-adenosine. Nat Biotechnol 1996; 14:1112-
5; PMID:9631061; http://dx.doi.org/10.1038/nbt0996-1112
72. Nolte A, Klussmann S, Bald R, Erdmann VA, F€urste JP. Mirror-
design of L-oligonucleotide ligands binding to L-arginine. Nat Bio-
technol 1996; 14:1116-9; PMID:9631062; http://dx.doi.org/10.1038/
nbt0996-1116
73. Williams KP, Liu X-H, Schumacher TNM, Lin HY, Ausiello DA,
Kim PS, Bartel DP. Bioactive and nuclease-resistant L-DNA ligand
of vasopressin. Proc Natl Acad Sci 1997; 94:11285-90;
PMID:9326601; http://dx.doi.org/10.1073/pnas.94.21.11285
74. Purschke WG, Radtke F, Kleinjung F, Klussmann S. A DNA Spie-
gelmer to staphylococcal enterotoxin B. Nucleic Acids Res 2003;
31:3027-32; PMID:12799428; http://dx.doi.org/10.1093/nar/gkg413
75. Vater A, Jarosch F, Buchner K, Klussmann S. Short bioactive Spie-
gelmers to migraineassociated calcitonin generelated peptide
rapidly identified by a novel approach: TailoredSELEX. Nucleic
Acids Res 2003; 31:e130-e; PMID:14576330; http://dx.doi.org/
10.1093/nar/gng130
76. EulbergD, Buchner K,Maasch C, Klussmann S. Development of an auto-
mated in vitro selection protocol to obtain RNA-based aptamers: identifi-
cation of a biostable substance P antagonist. Nucleic Acids Res 2005; 33:
e45-e; PMID:15745995; http://dx.doi.org/10.1093/nar/gni044
77. Faulhammer D, Eschgaller B, Stark S, Burgstaller P, Englberger W,
Erfurth J, Kleinjung F, Rupp J, Vulcu SD, Schroder W. Biostable
aptamers with antagonistic properties to the neuropeptide nocicep-
tin/orphanin FQ. RNA 2004; 10:516-27; PMID:14970396; http://dx.
doi.org/10.1261/rna.5186504
78. Leva S, Lichte A, Burmeister J, Muhn P, Jahnke B, Fesser D, Erfurth J,
Burgstaller P, Klussmann S. GnRH binding RNA and DNA Spie-
gelmers: a novel approach toward GnRH antagonism. Chem Biol
2002; 9:351-9; PMID:11927260; http://dx.doi.org/10.1016/S1074-
5521(02)00111-4
79. Jarosch F, Buchner K, Klussmann S. In vitro selection using a dual
RNA library that allows primerless selection. Nucleic Acids Res 2006;
34:e86-e; PMID:16855281; http://dx.doi.org/10.1093/nar/gkl463
80. Helmling S, Maasch C, Eulberg D, Buchner K, Schr€oder W, Lange C,
Vonhoff S, Wlotzka B, Tsch€op MH, Rosewicz S. Inhibition of ghrelin
action in vitro and in vivo by an RNA-Spiegelmer. Proc Natl Acad
Sci U S A 2004; 101:13174-9; PMID:15329412; http://dx.doi.org/
10.1073/pnas.0404175101
81. Sundaram P, Kurniawan H, Byrne ME, Wower J. Therapeutic RNA
aptamers in clinical trials. Eur J Pharm Sci 2013; 48:259-71;
PMID:23142634; http://dx.doi.org/10.1016/j.ejps.2012.10.014
82. 2016 NPA. NOXXON Pharma AG 2016.
83. Yatime L, Maasch C, Hoehlig K, Klussmann S, Andersen GR, Vater
A. Structural basis for the targeting of complement anaphylatoxin
C5a using a mixed L-RNA/L-DNA aptamer. Nat Commun 2015;
6:6481; PMID:25901944; http://dx.doi.org/10.1038/ncomms7481
84. Wang Z, Xu W, Liu L, Zhu TF. A synthetic molecular system capable of
mirror-image genetic replication and transcription. Nat Chem 2016;
8:698-704; PMID:27325097; http://dx.doi.org/10.1038/nchem.2517
85. Kuwahara M, Nagashima J-i, Hasegawa M, Tamura T, Kitagata R,
Hanawa K, Hososhima S-i, Kasamatsu T, Ozaki H, Sawai H. System-
atic characterization of 20-deoxynucleoside-50-triphosphate analogs
as substrates for DNA polymerases by polymerase chain reaction
and kinetic studies on enzymatic production of modified DNA.
Nucleic Acids Res 2006; 34:5383-94; PMID:17012278; http://dx.doi.
org/10.1093/nar/gkl637
86. MacPherson IS, Temme JS, Habeshian S, Felczak K, Pankiewicz K,
Hedstrom L, Krauss IJ. Multivalent glycocluster design through




































directed evolution. Angew Chem Int Ed 2011; 50:11238-42;
PMID:22191092; http://dx.doi.org/10.1002/anie.201105555
87. Temme JS, MacPherson IS, DeCourcey JF, Krauss IJ. High tempera-
ture SELMA: Evolution of DNA-supported oligomannose clusters
which are tightly recognized by HIV bnAb 2G12. J Am Chem Soc
2014; 136:1726-9; PMID:24446826; http://dx.doi.org/10.1021/
ja411212q
88. Tolle F, Br€andle GM, Matzner D, Mayer G. A Versatile approach
towards nucleobasemodified aptamers. Angew Chem Int Ed
2015; 54:10971-4; PMID:26224087; http://dx.doi.org/10.1002/
anie.201503652
89. Horiya S, MacPherson IS, Krauss IJ. Recent strategies targeting HIV
glycans in vaccine design. Nat Chem Biol 2014; 10:990-9;
PMID:25393493; http://dx.doi.org/10.1038/nchembio.1685
90. Temme JS, Drzyzga MG, MacPherson IS, Krauss IJ. Directed Evolu-
tion of 2G12Targeted Nonamannose Glycoclusters by SELMA.
Chem Eur J 2013; 19:17291-5; PMID:24227340; http://dx.doi.org/
10.1002/chem.201303848
91. Veedu R, Burri H, Kumar P, Sharma P, Hrdlicka P, Vester B, Wengel
J. Polymerase-directed synthesis of C5-ethynyl locked nucleic acids.
Bioorg Med Chem Lett 2010; 20:6565-8; PMID:20932755; http://dx.
doi.org/10.1016/j.bmcl.2010.09.044
92. Zhang L, Yang Z, Sefah K, Bradley KM, Hoshika S, Kim M-J,
Kim H-J, Zhu G, Jimenez E, Cansiz S. Evolution of functional
six-nucleotide DNA. J Am Chem Soc 2015; 137:6734-7;
PMID:25966323; http://dx.doi.org/10.1021/jacs.5b02251
93. Thyer R, Ellefson J. Synthetic biology: New letters for life’s alphabet.
Nature 2014; 509:291-2; PMID:24805244; http://dx.doi.org/10.1038/
nature13335
94. Sefah K, Yang Z, Bradley KM, Hoshika S, Jimenez E, Zhang L, Zhu G,
Shanker S, Yu F, Turek D. In vitro selection with artificial expanded
genetic information systems. Proc Natl Acad Sci 2014; 111:1449-54;
PMID:24379378; http://dx.doi.org/10.1073/pnas.1311778111
95. Georgiadis MM, Singh I, Kellett WF, Hoshika S, Benner SA, Richards
NG. Structural basis for a six nucleotide genetic alphabet. J Am
Chem Soc 2015; 137:6947-55; PMID:25961938; http://dx.doi.org/
10.1021/jacs.5b03482
96. Latham JA, Johnson R, Toole JJ. The application of a modified nucle-
otide in aptamer selection: novel thrombin aptamers containing-(1-
pentynyl)-20-deoxyuridine. Nucleic Acids Res 1994; 22:2817-22;
PMID:7519769; http://dx.doi.org/10.1093/nar/22.14.2817
97. Jensen KB, Atkinson BL, Willis MC, Koch TH, Gold L. Using in vitro
selection to direct the covalent attachment of human immunodefi-
ciency virus type 1 Rev protein to high-affinity RNA ligands. Proc
Natl Acad Sci 1995; 92:12220-4; PMID:8618873; http://dx.doi.org/
10.1073/pnas.92.26.12220
98. Battersby TR, Ang DN, Burgstaller P, Jurczyk SC, Bowser MT,
Buchanan DD, Kennedy RT, Benner SA. Quantitative analysis of
receptors for adenosine nucleotides obtained via in vitro selection
from a library incorporating a cationic nucleotide analog. J Am
Chem Soc 1999; 121:9781-9; PMID:11543572; http://dx.doi.org/
10.1021/ja9816436
99. Vaish NK, Larralde R, Fraley AW, Szostak JW, McLaughlin LW. A
novel, modification-dependent ATP-binding aptamer selected from
an RNA library incorporating a cationic functionality. Biochemistry
2003; 42:8842-51; PMID:12873145; http://dx.doi.org/10.1021/
bi027354i
100. Shoji A, Kuwahara M, Ozaki H, Sawai H. Modified DNA aptamer
that binds the (R)-isomer of a thalidomide derivative with high enan-
tioselectivity. J Am Chem Soc 2007; 129:1456-64; PMID:17263432;
http://dx.doi.org/10.1021/ja067098n
101. Imaizumi Y, Kasahara Y, Fujita H, Kitadume S, Ozaki H, Endoh
T, Kuwahara M, Sugimoto N. Efficacy of base-modification on
target binding of small molecule DNA aptamers. J Am Chem
Soc 2013; 135:9412-9; PMID:23734784; http://dx.doi.org/10.1021/
ja4012222
102. Li M, Lin N, Huang Z, Du L, Altier C, Fang H, Wang B. Selecting
aptamers for a glycoprotein through the incorporation of the boronic
acid moiety. J Am Chem Soc 2008; 130:12636-8; PMID:18763762;
http://dx.doi.org/10.1021/ja801510d
103. Vaught JD, Bock C, Carter J, Fitzwater T, Otis M, Schneider D,
Rolando J, Waugh S, Wilcox SK, Eaton BE. Expanding the chemistry
of DNA for in vitro selection. J Am Chem Soc 2010; 132:4141-51;
PMID:20201573; http://dx.doi.org/10.1021/ja908035g
104. Santoro SW, Joyce GF, Sakthivel K, Gramatikova S, Barbas CF. RNA
cleavage by a DNA enzyme with extended chemical functionality. J
Am Chem Soc 2000; 122:2433-9; PMID:11543272; http://dx.doi.org/
10.1021/ja993688s
105. Kimoto M, Yamashige R, Matsunaga K-i, Yokoyama S, Hirao I. Gen-
eration of high-affinity DNA aptamers using an expanded genetic
alphabet. Nat Biotechnol 2013; 31:453-7; PMID:23563318; http://dx.
doi.org/10.1038/nbt.2556
106. Hollenstein M, Hipolito CJ, Lam CH, Perrin DM. Toward the com-
binatorial selection of chemically modified DNAzyme RNase A
mimics active against all-RNA substrates. ACS Comb Sci 2013;
15:174-82; PMID:23485334; http://dx.doi.org/10.1021/co3001378
107. Gold L, Ayers D, Bertino J, Bock C, Bock A, Brody EN, Carter J,
Dalby AB, Eaton BE, Fitzwater T. Aptamer-based multiplexed prote-
omic technology for biomarker discovery. PLoS One 2010; 5:e15004;
PMID:21165148; http://dx.doi.org/10.1371/journal.pone.0015004
108. Davies DR, Gelinas AD, Zhang C, Rohloff JC, Carter JD, O’Connell
D, Waugh SM, Wolk SK, Mayfield WS, Burgin AB. Unique motifs
and hydrophobic interactions shape the binding of modified DNA
ligands to protein targets. Proc Natl Acad Sci 2012; 109:19971-6;
PMID:23139410; http://dx.doi.org/10.1073/pnas.1213933109
109. Ochsner UA, Katilius E, Janjic N. Detection of Clostridium difficile
toxins A, B and binary toxin with slow off-rate modified aptamers.
Diagn Microbiol Infect Dis 2013; 76:278-85; PMID:23680240; http://
dx.doi.org/10.1016/j.diagmicrobio.2013.03.029
110. Jhaveri S, Olwin B, Ellington AD. In vitro selection of phosphoro-
thiolated aptamers. Bioorg Med Chem Lett 1998; 8:2285-90;
PMID:9873529; http://dx.doi.org/10.1016/S0960-894X(98)00414-4
111. King DJ, Bassett SE, Li X, Fennewald SA, Herzog NK, Luxon BA,
Shope R, Gorenstein DG. Combinatorial selection and binding of
phosphorothioate aptamers targeting human NF-kB RelA (p65) and
p50. Biochemistry 2002; 41:9696-706; PMID:12135392; http://dx.doi.
org/10.1021/bi020220k
112. King DJ, Ventura DA, Brasier AR, Gorenstein DG. Novel combina-
torial selection of phosphorothioate oligonucleotide aptamers. Bio-
chemistry 1998; 37:16489-93; PMID:9843415; http://dx.doi.org/
10.1021/bi981780f
113. Lato SM, Ozerova NDS, He K, Sergueeva Z, Shaw BR, Burke DH.
Boron-containing aptamers to ATP. Nucleic Acids Res 2002;
30:1401-7; PMID:11884639; http://dx.doi.org/10.1093/nar/30.6.1401
RNA BIOLOGY 1245
D
ow
nl
oa
de
d 
by
 [
M
ur
do
ch
 U
ni
ve
rs
ity
 L
ib
ra
ry
] 
at
 0
1:
15
 3
1 
O
ct
ob
er
 2
01
7 
